Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Bristol-Myers Squibb Company
EIR
•Bristol-Myers Squibb Company•June 3, 2020

Bristol-Myers Squibb Company – FDA EIR, Jun 3, 2020

Record Details

An FDA inspection of Bristol Myers Squibb (formerly Celgene) at its Summit, NJ facility was conducted from May 26 to June 3, 2020. This pre-announced, high-priority inspection, guided by Compliance Program Guidance Manual 7348.810 for Sponsors, Contract Research Organizations, and Monitors, evaluated various aspects of the firm's clinical trial operations, including monitoring adequacy, protocol deviations, adverse event reporting, and record retention.

Significantly, no Form FDA-483, Inspectional Observations, was issued at the conclusion of the inspection. However, two discussion items were raised with management. Firstly, the FDA noted the absence of a formalized User Acceptance Testing (UAT) procedure prior to performing UAT activities, suggesting a need for better documentation. Secondly, a delay was identified in resolving a protocol deviation at Site 401, where a lack of Principal Investigator oversight was first noted in March 2016 and not resolved until May 2017. While the issue was eventually corrected, the FDA suggested the sponsor could have provided more timely oversight.

Bristol Myers Squibb management acknowledged these discussion items, expressing appreciation for the feedback and committing to address them by modifying their procedures to enhance future FDA audits. No samples were collected, and no refusals were encountered during the inspection.

Company
Bristol-Myers Squibb Company
Inspection date
June 3, 2020
Product type
drugs
Office
New Jersey District Office
People
  • C.L. Beach (company_representative)
  • Samit Hirawat (recipient)
  • Jasjit Hundal (company_representative)
  • Beatrice Roberts (company_representative)
  • Nina Yang (investigator)
View Company Profile

ID · ceb890a7-c101-4a8a-a3c3-8bc64d805436

Other documents for Bristol-Myers Squibb Company
  • 483 - 2025-07-18July 18, 2025
  • 483 - 2024-12-06December 6, 2024
  • 483 - 2023-06-16June 16, 2023
  • EIR - 2022-03-14March 14, 2022
  • 483 - 2021-02-19February 19, 2021

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Bristol-Myers Squibb Company
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.